视神经脊髓炎谱系疾病的临床特点及康复疗效分析

Abstract
Figure/Table
References (24)
Related Citation (6)

Download: PDF (840 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical features and rehabilitation prognosis of neuromyelitis spectrum diseases. Methods The clinical data of 7 patients with diagnosed optic neuromyelitis spectrum disease admitted to China Rehabilitation Research Center, Beijing Boai Hospital from January 2016 to October 2018 were retrospectively analyzed, their clinical characteristics and obstacle points were analyzed, and changes in activity of daily living (ADL) ability were observed, and the rehabilitation prognosis was compared. Results The 7 patients showed different degrees of limb motor dysfunction, sensory dysfunction, urinary bowel disorder, abnormal vision and emotional disorder, all of which required ADL. After systematic and standardized rehabilitation treatment, patients′ functional dysfunction and ADL ability were significantly improved（P ＜ 0.01）. Conclusion Early and active rehabilitation therapy can reduce the dysfunction of patients and improve the ADL ability.

Key words： Neuromyelitis optica spectrum disorder Aquaporin-4 Optic neuritis Transverse myelitis Rehabilitation treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Ping HE Jingjie LIU Lixu HU Xueyan▲

Cite this article:

LIU Ping HE Jingjie LIU Lixu HU Xueyan▲. Clinical characteristics and rehabilitation effect of neuromyelitis spectrum diseases[J]. 中国医药导报, 2019, 16(24): 185-189.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I24/185

[1] Wingerchuk DM，Banwell B，Bennett JL，et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders [J]. Neurology，2015，85（2）：177-189.
[2] Wingerchuk DM. Neuromyelitis optica：new findings on pathogenesis [J]. Int Rev Neurobiol，2007，79：665-688.
[3] Jacob A，McKeon A，Nakashima I，et al. Current concept of neuromyelitis optica（NMO）and NMO spectrum disorders [J]. Neurol Neurosurg Psychiatry，2013，84（8）：922-930.
[4] Flanagan EP，Cabre P，Weinshenker BG，et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum [J]. Ann Neurol，2016，79（5）：775-783.
[5] Davoudi V，Keyhania K，Bove RM，et al. Immunology of neuromyelitis optica during pregnancy [J]. Neurol Neuroimmunol Neuroinflamm，2016，3（6）：e288.
[6] Pandit L，Asgari N，Apiwattanakul M，et al. Demographic and clinical features of neuromyelitis optica：A review [J]. Mult Scler，2015，21（7）：845-853.
[7] Nagelhus EA，Ottersen OP. Physiological roles of aquaporin-4 in brain [J]. Physiol Rev，2013，93（4）：1543-1562.
[8] Yang X，Ransom BR，Ma JF. The role of AQP4 in neuromyelitis optica：More answers，more questions [J]. J Neuroimmunol，2016，298：63-70.
[9] Badaut J，Fukuda AM，Jullienne A，et al. Aquaporin and brain diseases [J]. Biochim Biophys Acta，2014，1840（5）：1554-1565.
[10] Jin X，Pei S，liu Y，et al. Clinical analysis of neuromyelitis optica presenting as intractable nausea，vomiting and hiccups [J]. Int J Neurosci，2017；127（10）：854-858.
[11] 尤小凡，胡洪涛，叶静.视神经脊髓炎谱系疾病患者脑干损害的临床和影像学特点[J].中风与神经疾病杂志，2014，31（9）：794-798.
[12] Joshi P，Lanford J，Bourke D. Neuromyelitis optica presenting as acute bilateral ptosis [J]. Pract Neurol，2017， 17（1）：57-59.
[13] Shinoda K，Matsushita T，Furuta K et al. Wall-eyed bilateral internuclear ophthalmoplegia （WEBINO） syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody [J]. Mult Scler，2011，17（7）：885-887.
[14] Su CL，Yeh JH，Lau CL. Persistent Hyperthermia in a Patient with Aquaporin-4-Antibody-Positive Neuromyelitis Optica Spectrum Disorder [J]. J Clin Neruol，2016，12（4）：515-516.
[15] Baba T，Nakashima I，Kanbayashi T，et al. Narcolepsy as an initial manifestation of neuromyelitis optica with antiaquaporin-4 antibody [J]. J Neurol，2009，256（2）：287-288.
[16] Belova AN，Bojko AN，Belova EM. Diagnostic criteria for neuromyelitisoptica spectrum disorders [J]. Zh Nevrol Psikhiatr Im S S Korsakova，2016，116（2）：32-40.
[17] Wingerchuk DM，Lennon VA，Lucchinetti CF，et al. The spectrum of neuromyelitis optica [J]. Lancet Neurol，2007，6（9）：805-815.
[18] Sato DK，Callegaro D，Lana-Peixoto MA，et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders [J]. Neurology，2014，82（6）：474-481.
[19] Wang J，Li X，Zhang DQ，et al. Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis [J]. J Neuroimmunol，2015，15（278）：26-29.
[20] Jarius S，Ruprecht K，Wildemann B，et al. Contrasting disease patterns in se ropositive and seronegative neuromyelitis optica：a multicentre study of 175 patients [J]. J Neuroinflammation，2012，9（1）：14.
[21] Zhong YH，Zhong ZG，Zhou Z，et al. Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sj?觟gren′s syndrome [J]. Neurol Sci，2017，38（2）：271-277.
[22] 武雷，黄德晖，杨扬，等.血清抗核抗体在视神经脊髓炎谱系疾病和多发性硬化中的分布[J].中国神经免疫学和神经病学杂志，2011，18（4）：243-245.
[23] Collongues N，de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica [J]. Ther Adv Neurol Disord，2016，9（3）：180-188.
[24] Montcuquet A，Collongues N，Papeix C，et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG，MOG-IgG，and seronegative neuromyelitis optica spectrum disorders [J]. Mult Scler，2017，23（10）：1377-1384.